Michael Chetrit

Cardiologist. AsistProf McGill,Former Imaging Fellow @ClevelandClinic. Prez, Canadian Society of MRI. Interested in Cardiac Amyloid and Pericardial diseases.

[American Society of Echocardiography @ASE360]

UPCOMING WEBINAR: Join us this Thursday from 12-1 PM ET for the #ASEWebinar, "Multimodality Imaging in Constrictive Pericarditis and Systemic Sclerosis!"

Sign up: https://t.co/P1ZOaSsz14

[Spittin' Chiclets @spittinchiclets]

The Montreal Canadiens had no business winning that Game 7, but somehow found a way to come out on top.

[Sharon Mulvagh MD FRCPC FASE FACC @HeartDocSharon]

Here we are at #CSEcho2026 kicking off in Beautiful #Vancouver. Day has been spectacular with a run along the Stanley Park Seawall, a few BOD mtgs and now learning about the athletes heart-physiology vs pathology? @amerjohri @dineshpmcc1 @ChetritMichael @AnaBaracCardio @ASE360

[Cornerstone Medical Education @Cornerstone_CME]

The 3rd Annual #ATTR Early-Career Research Forum Call-for-Abstracts is NOW LIVE!

Conducting research in ATTR? Submit your work for a chance to win the prestigious #WiesmanAward - and $100,000 in research funding.

Submit your abstract here: https://t.co/ORDISmkW4e

[Heart_BMJ @Heart_BMJ]

Pearls and pitfalls in the diagnosis and management of mitral annular calcification https://t.co/NVGYoNnIlc

[Michael Chetrit @ChetritMichael]

@AllanLKleinMD1 Huge congratz and long time deserved ! @AllanLKleinMD1

[Spittin' Chiclets @spittinchiclets]

The Montreal Canadiens are built to be long lasting sturdy wagon 💪

[Ahmad Masri @MasriAhmadMD]

Updated data on gene therapy in PKP2 cardiomyopathy/ARVC using LX2020

#ACC26 #CardioTwitter

[Allan L. Klein @AllanLKleinMD1]

It was a great privilege and honor to receive this award

[Ahmad Masri @MasriAhmadMD]

#ACC26 Mavacamten in adolescents with obstructive HCM. Results from SCOUT-HCM
Overall consistent with what was seen in adults. Requiring higher doses of drug. Small sample size but reassuring safety that isnt expected to diverge much from what was observed in adult trials (potentially even safer due to shorter disease duration, less comorbidities, less restrictive disease)

https://t.co/psIlV32nWZ

#CardioTwitter

[Ahmad Masri @MasriAhmadMD]

#ACC26 Great data from @maz_hanna et al
Rate of conversion from PYP/HDP negative to positive - typically over 3 years, and CTS/SS identifies the high risk group. This supports our current practice of repeat evaluation once every 2 years in CTS+
#CardioTwitter #MedIQACC26

[EACVI President @EACVIPresident]

📢 #EACVI2026

A key 🌍 platform where #CVImaging comes together to shape the future of our field.

📍 Milan | 📅 3–5 Dec

📝 Abstract: 21 May
📝 Clinical case: 2 June

Why should you submit your work?
Hear from Prof @VDelgadoGarcia 👇

🔗 https://t.co/zA8Oq578h8

@NAjmoneMarsan @rmanka_ @carpenter_jp @LunaGargani @andgiannopmd @PezelT @anatimoteo46040 @alessia_gimelli @EHJIMPEiC @EHJCVIEiC @Sarah_Moharem @denisamuraru @s_e_petersen @VDelgadoGarcia

[Spittin' Chiclets @spittinchiclets]

Listen to that POP from the Bell Centre after Newhook scored the equalizer.

ABSOLUTELY ELECTRIC ⚡️

[JACC Journals @JACCJournals]

Skip the non-contrast CT in #YesCCT aortic valve assessment? CCT indexed aortic valve calcium volume accurately Dx severe AS & predicts valve replacement or death w/out separate non-contrast CT in multicenter registry study https://t.co/RSI5VXPOAi #JACCIMG #cvImaging #vhdAS

[Julie Stewart-Binks @JSB_TV]

“[Nick Suzuki] is probably the most underrated two-way player in the league…” - HOF Mark Messier on @CBCOlympics after @TeamCanada win over Czechia. @CanadiensMTL

Full interview @cbcsports ➡️ https://t.co/bkwc7SDpSo #MilanoCortina2026

[Alex @ivandemigoal]

Jesus, Ivan

[Ahmad Masri @MasriAhmadMD]

Another real-world evaluation of mavacamten in oHCM from a registry (COLLIGO-HCM) showing:
1) Mavacamten is effective in relieving LVOT gradients and improving symptoms.
2) Study had a short term follow up (mean 35 weeks).
3) 60% improvement in NYHA class by 1 FC which was seen in EXPLORER as well. --> we discontinue patients who do not derive symptomatic benefit from commercial mavacamten/CMI
4) Safety consistent with EXPLORER (have to go to text not in the abstract), with somewhat shorter term follow up, as well as certain adjustments to dose initiation (such as some on 2.5 mg). Terminal doses are not mentioned (I could have missed that).
5) Mavacamten effects on LVOTO, NYHA class, and LVEF were somewhat consistent as a monotherapy or when with background medical therapy

https://t.co/NzQGIY8qOe

#CardioTwitter

[Miho.Fukui @Miho_Fukui_]

M-TEER is also effective for Atrial MR?
Yes, it is! From OCEAN cohort

#PCRTokyo #LBT #M-TEER @PCRonline @misako_desu @TomokiOchiai

[Amin Sabet, MD @AminSabetMD]

I’m excited to announce the launch of the Inflammatory Myocardial and Pericardial Disease Specialty Interest Group (SIG) within the American Society of Echocardiography (ASE). This SIG will serve as a dedicated platform for medical professionals involved in the diagnosis and management of inflammatory myocardial and pericardial diseases through cardiovascular imaging.

This will be a valuable opportunity to learn from leading experts from around the world, share knowledge, and expand professional networking within this growing field. I invite you to consider joining us.

As Chair of this SIG, I would like to sincerely thank ASE for supporting this initiative. I am also honored to be joined by Dr. Allan Klein of the Cleveland Clinic as Co-Chair of this group. Finally, I would like to thank the colleagues and committee members who have been willing to support this effort as we begin building this new community.

We look forward to growing this collaborative platform together

To learn more and join the SIG, please visit:

https://t.co/I2p0IKP4Ku

@ASE360
@AllanLKleinMD1 @AbbateAntonio @MerriBremer @MohamedAlKazaz @ChetritMichael @LehtonenJukka @Tahirkafil @SophieMavrogeni @MMukherjeeMD @RichardPalma @Bweber04 @MargaretPark @purviparwani @TomKMWang @DrHebaMD @DavidWienerMD

[Ahmad Masri @MasriAhmadMD]

Excellent paper here by Dr. Sheikh and Dr. Fontana et al. placing CMR ECV within context and clinical usefulness.

It is also a reminder that ATTR-CM is a fatal disease. Over 2.8 years, 40% died (enrolled over 13 years).

https://t.co/Npw2UPpo6s

#CardioTwitter